查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2129053

陰道炎治療市場：依疾病、產品、通路、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Vaginitis Therapeutics Market, By Disease, By Product, By Distribution Channel, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 302 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，陰道炎治療市場價值將達到 40.513 億美元，從 2026 年到 2033 年將以 8.1% 的複合年成長率成長。

治療陰道炎的藥物包括抗真菌藥物、抗生素和荷爾蒙藥物，用於治療陰道感染疾病。這些藥物能非常有效地緩解搔癢、分泌物和疼痛等症狀。

治療陰道炎的主要藥物類型包括硝基咪唑類、林可醯胺類抗生素、三唑類和咪唑類。硝基咪唑類是一種抗菌藥物，用於對抗寄生蟲、分枝桿菌以及厭氧革蘭氏陽性菌和革蘭氏陰性菌。它們可用於治療多種疾病，包括細菌性陰道炎、滴蟲病和外陰陰道念珠菌症，給藥途徑包括口服、局部用藥和陰道內給藥。最終使用者包括醫院、婦科中心、外科中心和診所。

陰道炎治療市場 - 市場動態

性行為感染感染（STI）的日益普及正在推動市場需求。

性行為感染傳染病（STI）病例的不斷增加，尤其是滴蟲病，是陰道炎治療市場的主要促進因素之一。這是因為人們越來越需要使用抗生素來有效治療這些疾病，以緩解症狀、預防併發症並控制感染疾病。例如，一項基於超過5萬名患者數據的研究（發表於2025年4月的《Cureus》雜誌，可透過美國國家生物技術資訊中心（NCBI）取得）顯示，性行為感染（STI）的盛行率為16.2%。預計這些疾病在全球範圍內的盛行率上升將增加對陰道炎治療的需求。日益加重的疾病負擔預計將進一步增加對有效陰道炎治療的需求。

陰道炎治療市場—市場細分分析：

全球陰道炎治療市場按疾病、產品、通路和地區細分。

細菌性陰道炎是陰道炎的常見亞型，通常需要使用抗生素治療。此外，隨著人們對各種類型陰道炎的認知不斷提高以及復發率的上升，抗生素療法在陰道炎治療市場中佔據了相當大的佔有率。例如，英國政府2026年5月的報告顯示，英格蘭的抗生素抗藥性血流感染疾病病例增加了13.1%，從18,103例增加到20,484例。特定細菌性血流感染疾病病例也從173,513例增加到183,990例，凸顯了細菌及其感染疾病日益成長的重要性，以及對有效抗菌藥物需求的不斷增加。這些趨勢表明，人們越來越需要有效的抗生素療法來控制細菌感染疾病。

從產品類型來看，處方藥在陰道炎治療市場佔了很大比例。這是因為這些藥物能夠為嚴重的、慢性的和複雜的陰道感染疾病提供專業的、醫療管理的治療。例如，根據印度新聞資訊局（PIB）的數據顯示，截至2026年3月，印度國內藥品市場規模為600億美元，預計2030年將成長至1,300億美元。印度還擁有約6萬個涵蓋60個治療領域的非專利品牌。印度的製藥業產量位居全球第三，市場規模位居全球第十一，擁有超過3,000家公司和10,500個製造地。這種成長正在推動處方藥的供應、可及性和分銷，以滿足多樣化的治療需求。

陰道炎治療市場—區域分析

北美在陰道炎治療市場佔據重要地位，這主要得益於該地區細菌和真菌感染疾病的高發生率、完善的醫療保健基礎設施以及日益增強的生殖健康意識。例如，美國疾病管制與預防中心 (CDC) 估計，到 2025 年 5 月，真菌性疾病每年將在美國造成約 7,300 人死亡、13 萬人住院和 1,300 萬人次門診就診。 CDC 估計，真菌感染疾病每年對美國造成的經濟負擔約為 190 億美元，凸顯了真菌相關感染疾病的高發生率。這些趨勢表明，北美對有效的陰道炎治療方法和先進療法有著巨大的需求。

目錄

第1章：陰道炎治療市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：陰道炎治療藥物的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：陰道炎治療產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：陰道炎治療市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：陰道炎治療藥物市場趨勢

  • 2025年陰道炎治療市佔分析
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 陰道炎治療市場：依疾病分類

  • 概述
    • 基於細分市場的市佔率分析：依疾病分類
    • 抗菌劑
    • 荷爾蒙
    • 抗真菌劑

第8章 陰道炎治療市場：依產品分類

  • 概述
    • 基於細分市場的市佔率分析：按產品
    • 處方
    • 非處方藥（OTC）

第9章 陰道炎治療市場：依通路分類

  • 概述
    • 基於細分市場的市場佔有率分析：按分銷管道分類
    • 零售藥房
    • 醫院藥房
    • 其他

第10章 陰道炎治療市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第11章：主要供應商分析：陰道炎治療產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Novartis AG
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • Glenmark Pharmaceuticals Ltd.
    • Sun Pharmaceutical Industries Limited
    • Viatris Inc.
    • Abbott Laboratories
    • Hologic, Inc.
    • Roche Diagnostics
    • AstraZeneca plc
    • Johnson & Johnson
    • Procter & Gamble Company
    • Lumavita AG
    • Organon & Co.
    • Alvogen
    • ANI Pharmaceuticals, Inc.
    • Bausch Health Companies Inc.
    • Others

第12章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7417

Vaginitis Therapeutics market size was valued at US$ 4,051.3 Million in 2025, expanding at a CAGR of 8.1% from 2026 to 2033.

Vaginitis therapeutics involves the administration of medications, including antifungals, antibiotics, and hormones, for the treatment of vaginal infections. Such medications are very effective in alleviating symptoms like itching, discharge, and pain.

The types of the major therapeutic agents for vaginitis include nitroimidazole drugs, lincosamide antibiotics, triazoles, and imidazoles. Nitroimidazole drugs are antimicrobial drugs and are employed against parasitic, mycobacterial, and anaerobic Gram-positive and Gram-negative bacteria. The route of administration can be oral, topical, and vaginal for conditions such as bacterial vaginosis, trichomoniasis, vulvovaginal candidiasis, and many more. The end-users include hospitals, gynecology centers, surgery centers, and clinics.

Vaginitis Therapeutics Market- Market Dynamics

Increasing Prevalence of Sexually Transmitted Diseases (STDs) to Propel Market Demand

The rising number of sexually transmitted diseases (STDs), especially trichomoniasis, is one of the major drivers in the Vaginitis Therapeutics market due to the increasing need to treat such illnesses properly using antimicrobial drugs in order to relieve the symptoms, prevent complications, and handle the infection. For instance, in April 2025, according to a study published in Cureus and available through the National Centre for Biotechnology Information (NCBI), based on the results of more than 50,000 patients, the prevalence of sexually transmitted diseases (STDs) was recorded at 16.2%, and it can be expected that an increase in the prevalence rate of such diseases worldwide will lead to an increase in the demand for vaginitis treatments and remedies. This growing disease burden is expected to increase demand for effective vaginitis therapeutics and treatment options.

Vaginitis Therapeutics Market- Segmentation Analysis:

The Global Vaginitis Therapeutics market is segmented on the basis of Disease, Product, Distribution Channel, and Region.

Antibacterial therapies hold a significant share in the Vaginitis Therapeutics market since bacterial vaginosis, that is one of the common subtypes of vaginitis, always requires the use of antibacterial treatment, along with an increase in the awareness regarding different types of vaginitis and an increase in the incidence rate of recurrence of infection. For instance, in May 2026, according to the UK government, the number of antibiotic-resistant bloodstream infections in England increased by 13.1% from 18,103 cases to 20,484 cases. Also, the selected bacterial bloodstream infections increased from 173,513 cases to 183,990 cases, showing the increasing importance of bacteria and their infections and the growing requirement of effective antibacterials. These trends highlight the growing demand for effective antibacterial therapies to manage bacterial infections.

In terms of product type, prescription therapeutics hold a significant share in the Vaginitis Therapeutics market, as these drugs provide a specialised and medically controlled way of treating severe, chronic, and complex vaginal infections. For instance, in March 2026, according to the Press Information Bureau (PIB), the value of the domestic pharma market in India stood at USD 60,000 million and is expected to increase to USD 130,000 million in 2030, while India has approximately 60,000 generic brands in 60 therapeutic segments. The pharma sector in India ranks third in the world in terms of volume and eleventh in terms of value, and the Indian pharma sector consists of more than 3,000 companies with 10,500 manufacturing units. This growth strengthens the availability, accessibility, and adoption of prescription therapeutics across diverse treatment needs.

Vaginitis Therapeutics Market- Geographical Insights

North America holds a notable place in the Vaginitis Therapeutics market, driven by the prevalence of infections such as bacteria and fungi, developed healthcare infrastructure, and increased awareness of reproductive health. For instance, in May 2025, according to the U.S. Centres for Disease Control and Prevention (CDC), the number of fatalities, hospitalisations, and outpatient visits because of fungal diseases in the United States is estimated to be around 7,300 deaths, 130,000 hospitalisations, and 13 million outpatient visits annually from the fungal diseases in the United States. The CDC estimates that the economic burden of fungal infections in the United States is around $19 billion per annum, signifying the high prevalence of fungi-related infections. These trends underscore North America's demand for effective vaginitis therapeutics and advanced treatment options.

Vaginitis Therapeutics Market- Competitive Landscape:

The Vaginitis Therapeutics market is highly fragmented with intense competition among different global companies like Pfizer Inc., Merck & Co. Inc., Bayer AG, Lupin Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. There is an increasing focus of the firms on improving their market position through innovations, R&D spending, joint ventures, and diversifications. In January 2025, Bayer AG intensified its association with Yuhan Corporation through signing a domestic supply contract for its Canesten products in South Korea, which will help make the Canesten products available for treating vaginal fungal infection and vaginitis. These strategic initiatives are expected to intensify competition and drive innovation across the Vaginitis Therapeutics market.

Recent Developments:

In January 2026, Roche Diagnostics gained the CE mark approval of its Cobas(R) BV/CV Assay, which is a molecular diagnostic test that is intended to help diagnose bacterial vaginosis and Candida vaginitis.

In June 2025, Organon teamed up with Evvy to offer increased availability of XACIATO(R) (clindamycin phosphate) vaginal gel 2%, which has been FDA-approved to treat bacterial vaginosis.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VAGINITIS THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Limited
  • Viatris Inc.
  • Abbott Laboratories
  • Hologic, Inc.
  • Roche Diagnostics
  • AstraZeneca plc
  • Johnson & Johnson
  • Procter & Gamble Company
  • Lumavita AG
  • Organon & Co.
  • Alvogen
  • ANI Pharmaceuticals, Inc.
  • Bausch Health Companies Inc.
  • Others

GLOBAL VAGINITIS THERAPEUTICS MARKET, BY DISEASE- MARKET ANALYSIS, 2020 - 2033

  • Anti-bacterial
  • Hormone
  • Anti-fungal

GLOBAL VAGINITIS THERAPEUTICS MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033

  • Prescription
  • Over-the-counter (OTC)

GLOBAL VAGINITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033

  • Retail Pharmacies
  • Hospital Pharmacies
  • Others

GLOBAL VAGINITIS THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Vaginitis Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Vaginitis Therapeutics Market Snippet by Disease
    • 2.1.2. Vaginitis Therapeutics Market Snippet by Product
    • 2.1.3. Vaginitis Therapeutics Market Snippet by Distribution Channel
    • 2.1.4. Vaginitis Therapeutics Market Snippet by Country
    • 2.1.5. Vaginitis Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Vaginitis Therapeutics Key Market Trends

  • 3.1. Vaginitis Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Vaginitis Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Vaginitis Therapeutics Market Opportunities
  • 3.4. Vaginitis Therapeutics Market Future Trends

4. Vaginitis Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Vaginitis Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Vaginitis Therapeutics Market Landscape

  • 6.1. Vaginitis Therapeutics Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Vaginitis Therapeutics Market - By Disease

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease, 2025 & 2033 (%)
    • 7.1.2. Anti-bacterial
    • 7.1.3. Hormone
    • 7.1.4. Anti-fungal

8. Vaginitis Therapeutics Market - By Product

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Product, 2025 & 2033 (%)
    • 8.1.2. Prescription
    • 8.1.3. Over-the-counter (OTC)

9. Vaginitis Therapeutics Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
    • 9.1.2. Retail Pharmacies
    • 9.1.3. Hospital Pharmacies
    • 9.1.4. Others

10. Vaginitis Therapeutics Market - By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Vaginitis Therapeutics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Vaginitis Therapeutics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.16. Denmark
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.16.3. Denmark Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.3.16.4. Denmark Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.16.5. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.17. Rest of Europe
      • 10.3.17.1. Overview
      • 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.17.3. Rest of the Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.3.17.4. Rest of the Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.17.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Vaginitis Therapeutics Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.15. Taiwan
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.15.3. Taiwan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.4.15.4. Taiwan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.15.5. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.16. Vietnam
      • 10.4.16.1. Overview
      • 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.16.3. Vietnam Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.4.16.4. Vietnam Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.16.5. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.17. Rest of APAC
      • 10.4.17.1. Overview
      • 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.17.3. Rest of APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.4.17.4. Rest of APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.17.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Vaginitis Therapeutics Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Vaginitis Therapeutics Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.13. Iran
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.13.3. Iran Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.6.13.4. Iran Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.13.5. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.14. Qatar
      • 10.6.14.1. Overview
      • 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.14.3. Qatar Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.6.14.4. Qatar Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.14.5. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.15. Rest of MEA
      • 10.6.15.1. Overview
      • 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.15.3. Rest of MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
      • 10.6.15.4. Rest of MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.15.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)

11. Key Vendor Analysis- Vaginitis Therapeutics Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Novartis AG
    • 11.2.2. Cipla Limited
    • 11.2.3. Dr. Reddy's Laboratories Ltd.
    • 11.2.4. Glenmark Pharmaceuticals Ltd.
    • 11.2.5. Sun Pharmaceutical Industries Limited
    • 11.2.6. Viatris Inc.
    • 11.2.7. Abbott Laboratories
    • 11.2.8. Hologic, Inc.
    • 11.2.9. Roche Diagnostics
    • 11.2.10. AstraZeneca plc
    • 11.2.11. Johnson & Johnson
    • 11.2.12. Procter & Gamble Company
    • 11.2.13. Lumavita AG
    • 11.2.14. Organon & Co.
    • 11.2.15. Alvogen
    • 11.2.16. ANI Pharmaceuticals, Inc.
    • 11.2.17. Bausch Health Companies Inc.
    • 11.2.18. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us